ArticleBritish journal of pharmacology2017
Cannabinoid CB
Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Animal Models for Anorexia Nervosa-A Systematic Review.Frontiers in human neuroscience · 2020Pooled it
- Activity Based Anorexia as an Animal Model for Anorexia Nervosa-A Systematic Review.Frontiers in nutrition · 2019Pooled it
- Development and Preclinical Safety Evaluation of an Injectable β-Caryophyllene Nanoemulsion.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Comprehensive insights into emerging advances in the Neurobiology of anorexia.Journal of advanced research · 2026Review
- Coordinated epigenetic dysregulation of CNR1 and FAAH genes drives endocannabinoid system dysfunction in anorexia nervosa.Journal of eating disorders · 2025Article
- Anorexia-Induced Hypoleptinemia Drives Adaptations in the JAK2/STAT3 Pathway in the Ventral and Dorsal Hippocampus of Female Rats.Nutrients · 2024Article
- The relationship between cannabis and anorexia nervosa: a scoping review.Journal of eating disorders · 2023Article
- Induction of Activity-Regulated Cytoskeleton-Associated Protein and c-Fos Expression in an Animal Model of Anorexia Nervosa.Nutrients · 2023Article
- Article
- A next generation sequencing gene panel for use in the diagnosis of anorexia nervosa.Eating and weight disorders : EWD · 2022Article
- Cortical reorganization of the glutamate synapse in the activity-based anorexia rat model: Impact on cognition.Journal of neurochemistry · 2022Article
- Effects of Δ9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review.International journal of environmental research and public health · 2022Review
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- On the Role of Central Type-1 Cannabinoid Receptor Gene Regulation in Food Intake and Eating Behaviors.International journal of molecular sciences · 2021Review
- Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.Biomolecules · 2020Review
- The novel cannabinoid CBBritish journal of pharmacology · 2019Article
- MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update.European journal of endocrinology · 2019Review
- Endocannabinoids in Body Weight Control.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Hypothesis: Clues From Mammalian Hibernation for Treating Patients With Anorexia Nervosa.Frontiers in psychology · 2018Article
- Cannabinoid CBBritish journal of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAnorexia nervosa (AN) is a serious psychiatric condition characterized by excessive body weight loss and disturbed perceptions of body shape and size, often associated with excessive physical activity. There is currently no effective drug-related therapy of this disease and this leads to high relapse rate. Clinical data suggest that a promising therapy to treat and reduce reoccurrence of AN may be based on the use of drugs that target the endocannabinoid (EC) system, which appears dysregulated in AN patients. EXPERIMENTAL APPROACH: The activity-based anorexia (ABA) rodent model mimics the severe body weight loss and increased physical activity, as well as the neuroendocrine disturbances (i.e. hypoleptinaemia and hypercortisolaemia) in AN. This study investigated whether cannabinoid agonists can effectively modify anorexic-like behaviours and neuroendocrine changes in rats subjected to a repeated ABA regime that mimics the human condition in which patients repeatedly undergo a recovery and illness cycle. KEY
resultsOur data show that subchronic treatment with both the natural CB CONCLUSION AND IMPLICATIONS: Taken together, our results further demonstrate the involvement of the EC system in AN pathophysiology and that strategies which modulate EC signalling are useful to treat this disorder, specifically in patients where physical hyperactivity plays a central role in its progression and maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.